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Abstract
Akt kinases are key signaling components in proliferation-competent and post-mitotic cells.
Here, we sought to create a conditionally-inducible form of active Akt for both in vitro and in
vivo applications. We fused a ligand-responsive Destabilizing Domain (DD) derived from E.
coli dihydrofolate reductase to a constitutively active mutant form of Akt1, Akt(E40K). Prior
work indicated that such fusion proteins may be stabilized and induced by a ligand, the anti-
biotic Trimethoprim (TMP). We observed dose-dependent, reversible induction of both total
and phosphorylated/active DD-Akt(E40K) by TMP across several cellular backgrounds in
culture, including neurons. Phosphorylation of FoxO4, an Akt substrate, was significantly
elevated after DD-Akt(E40K) induction, indicating the induced protein was functionally
active. The induced Akt(E40K) protected cells from apoptosis evoked by serum deprivation
and was neuroprotective in two cellular models of Parkinson’s disease (6-OHDA and MPP+
exposure). There was no significant protection without induction. We also evaluated Akt
(E40K) induction by TMP in mouse substantia nigra and striatum after neuronal delivery via
an AAV1 adeno-associated viral vector. While there was significant induction in striatum,
there was no apparent induction in substantia nigra. To explore the possible basis for this
difference, we examined DD-Akt(E40K) induction in cultured ventral midbrain neurons. Both
dopaminergic and non-dopaminergic neurons in the cultures showed DD-Akt(E40K) induc-
tion after TMP treatment. However, basal DD-Akt(E40K) expression was 3-fold higher for
dopaminergic neurons, resulting in a significantly lower induction by TMP in this population.
Such findings suggest that dopaminergic neurons may be relatively inefficient in protein
degradation, a property that could relate to their lack of apparent DD-Akt(E40K) induction in
vivo and to their selective vulnerability in Parkinson’s disease. In summary, we generated
an inducible, biologically active form of Akt. The degree of inducibility appears to reflect cel-
lular context that will inform the most appropriate applications for this and related reagents.
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Introduction
The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a critical down-
stream effector of the PI3K signaling pathway [1–5]. Akt is comprised of three highly con-
served domains: an N- terminal pleckstrin homology (PH) domain, a kinase domain with
serine/threonine phosphotransfer specificity, and a hydrophobic C-terminal tail. Canonical
Akt activation begins when a trophic factor binds to a receptor tyrosine kinase and activates
PI3K, which phosphorylates lipids at the plasma membrane to generate phosphatidylinositol
3,4 bisphosphate (PI3,4P2) and phosphatidylinositol 3,4,5 triphosphate (PIP3). These phos-
phorylated lipids exhibit high affinity for the Akt PH domain and lead to its recruitment to the
inner surface of the plasma membrane. Membrane translocation of Akt and binding of its PH
domain to phospholipids leads to a conformational change from a “PH-in” to a “PH-out” con-
formation, allowing access of upstream kinases to the kinase domain and phosphorylation at
two sites: Thr308 within the catalytic domain by PDK1 and Ser473 within the C-terminal
hydrophobic domain by mammalian target of rapamycin complex 2 (mTORC2) and other
kinases [6]. The degree to which the two canonical phosphorylation sites have distinct func-
tions has not been fully determined; however, it has been reported that while phosphorylation
of both sites is required for full catalytic activity, phosphorylation of the Thr308 site stimulates
enzymatic activity by an estimated 100-fold, whereas phosphorylation of the Ser473 site can
induce activity levels by an additional 7 to 10-fold [7–11].
Once Akt is in a catalytically active state, it can in turn interact with over 100 purported
substrates to induce a variety of downstream physiological effects, including cell growth, pro-
liferation, survival, and altered metabolism [1, 5]. While much of the focus on Akt’s functions
has been related to proliferation-competent cells, especially in cancer, important roles for Akt
have been defined in post-mitotic cells such as neurons. This includes promotion of neuronal
survival, differentiation and regeneration [12–14]. Abnormal Akt signaling has also been asso-
ciated with neuropsychiatric and neurodevelopmental disorders as well as with neurodegener-
ative disorders including prion disease and Parkinson’s disease (PD) [12, 15–19]. In the case of
PD, there is evidence for deficient Akt signaling in affected patient neurons [18, 19] and that
over-expression of constitutively active Akt promotes neuroprotection and axonal regenera-
tion in animal models of PD [20, 21].
Fully understanding the functional roles of Akt in cells and harnessing its activity for poten-
tial therapeutic applications has posed several challenges. Among these is that activation via
growth factor signaling or elevation of PI3K activity involves regulation of additional path-
ways, while over-expression has the potential drawback that the timing and level of protein
produced are difficult to control. Moreover, for possible therapeutic use, overexpressed Akt
poses the potential hazards of unregulated activity and in view of finding increased Akt activity
in a wide variety of human cancers, potential for promoting neoplasms. For these reasons, we
sought to develop a tunable, inducible form of Akt for use both in vitro and in vivo. To achieve
this, we drew on the Destabilizing Domain (DD) technology introduced by the laboratory of
Dr. Thomas Wandless [22]. This approach involves the fusion of a destabilizing protein
domain derived from E. coli dihydrofolate reductase (DHFR) to the protein of interest, confer-
ring instability to the entire fusion protein via proteasomal degradation. Stabilization of the
fusion protein is induced by the cell- and blood brain barrier-permeable, FDA approved anti-
biotic, Trimethoprim (TMP), which binds the DHFR domain and interferes with degradation
in a concentration-dependent manner [22]. This system has been validated in a variety of bio-
logical contexts, including parasites [23, 24], mammalian cell lines [22, 25–27], and rodent
brains [22, 26–28].
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Here, we describe the creation of an inducible DD-Akt using the constitutively active Akt1
(E40K) mutant. We have evaluated the system in cell culture and in brain and demonstrate
that DD-Akt(E40K) is inducible and physiologically active in both proliferating cells and post-
mitotic neurons. Intriguingly, our data suggest that the inducibility of DD-Akt(E40K) is
dependent on neuron type and region of expression within the brain. Such findings raise
potential limitations for use of DD-linked proteins in brain and may indicate differences in
susceptibility of specific neuron types to pathological processes in neurodegenerative diseases.
Materials and methods
Cell culture
HEK293T/17 cells (purchased from the ATCC, catalogue number CRL-11268) were grown in
DMEM supplemented with 10% FBS and penicillin/streptomycin. Cultures were transfected
using Lipofectamine 2000 (ThermoFisher Scientific) according to the manufacturer’s proto-
cols. Trimethoprim (TMP; Sigma-Aldrich; 10 μM) was added to cultures as indicated 24 h
after transfection, and protein extraction or immunofluorescence staining was performed 24 h
after treatment.
PC12 cells (originally derived in our lab [28]) were cultured as described previously [29] on
plastic cell culture dishes coated with rat tail collagen (Roche). Undifferentiated PC12 cells
were grown in RPMI 1640 medium supplemented with 10% heat inactivated horse serum
(Sigma), 5% FBS, and penicillin/streptomycin. For neuronal differentiation, cells were grown
in RPMI 1640 medium supplemented with 1% horse serum, penicillin/streptomycin, and 50
ng/ml final concentration of human recombinant NGF (kind gift of Genentech and Gemini
Bio-Products #300-174P). Lentivirus was added to the cultures at an approximate MOI of
5–10 on day 1–2 after plating for undifferentiated cultures and 4–5 days after NGF treatment
for differentiated cultures. 10 μM TMP was added to cultures 4–5 days after infection, and pro-
tein extraction was performed 24 h after treatment.
Primary cortical cultures were prepared as previously described [30]. Briefly, cortices were
isolated from E18 rat embryos, dissociated, and plated on poly-D-lysine (Sigma) coated plates
at a density of 3 x 105 cells/well. Cultures were maintained in Neurobasal medium (Thermo-
Fisher Scientific) supplemented with 2% B-27 (ThermoFisher Scientific) and 0.5 mM gluta-
mine (ThermoFisher Scientific). Half of the medium was changed every 3 days after plating.
Lentivirus was added to the cultures at an approximate MOI of 5–10 on day 5–7 in vitro and
protein extraction was performed 4–7 days after infection.
Ventral midbrain dopaminergic neurons from P0-P3 rats were dissected, dissociated, and
plated on a confluent glial monolayer as described previously [31]. Briefly, 1 mm3 blocks were
dissected from the substantia nigra of a coronal midbrain slice, according to anatomical land-
marks, and enzymatically dissociated in a papain solution for 20–30 minutes. Digested tissue
blocks were rinsed and triturated 10 times with large-bore tech tips, 10 times with medium-
bore tech tips, and 10 times with small-bore tech tips. Cells were centrifuged, resuspended in
SF1C medium, and plated at a density of 80,000 cells per dish on top of a glial monolayer. Cul-
tures were treated with GDNF (10 ng/ml) and processed as needed for experiments. Lentivirus
was added to the cultures at an approximate MOI of 10 on day 6–7 in vitro, 10 μM TMP was
added to cultures 6–10 days after infection, immunofluorescence was performed after 4 days
of TMP treatment.
Cell death paradigms
Serum deprivation. For serum deprivation of undifferentiated PC12 cells infected with
lentivirus expressing DD-Akt(E40K), cells were detached from wells with serum-free RPMI
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1640 and pelleted at 1500 rpm for 5 min. Pellets were washed in serum-free RPMI 1640, repel-
leted, resuspended in serum-free RPMI 1640 and plated at a density of 5 x 105 cells/ml in the
presence and absence of either 50 ng/ml of NGF or 10 μM TMP. Cells were analyzed for sur-
vival 24 h after serum deprivation.
PD toxins. For neuronal PC12 cells, 10 mM stock solutions of 6-hydroxydopamine
(Tocris) or 1-methyl-4-phenylpyridinium (MPP+) (Sigma) diluted in water were freshly pre-
pared just before each experiment. 6-OHDA was used at final concentrations ranging from
100 to 150 μM, and MPP+ was used at a final concentration of 0.25 mM, for 16–24 h.
Quantification of cell survival in vitro
For PC12 cells infected with lentiviral particles (typically achieving a 50% transduction rate in
undifferentiated PC12 cells and 75% transduction rate in differentiated PC12 cells) and treated
with PD toxins or deprived of serum, cell survival was assessed by counting the total cell popu-
lation as previously described [32].
Cloning
DD-Akt(E40K). The DHFR-derived DD-YFP gene insert in a pBMN vector was obtained
from Addgene (Plasmid #29325). The HA-Akt1(E40K) gene insert [33] from hereon in called
Akt(E40K)) was amplified using PCR and primers as follows: Fwd 5' gcgcatgcTACCCA
TACGATGTTCCAGATT-3'and Rev 5'-atccgcggTCAGGCTGTGCCACTGG-3'. The
amplified Akt(E40K) gene was inserted 3’ of the DD domain, replacing YFP, in a pBMN vector
using restriction sites Sph1 and SacII to create pBMN-DD-Akt(E40K). The entire DD-Akt
(E40K) gene was then inserted using restriction sites BamHI and SacII and blunt-end ligation
into the overexpression vector pWPI (Addgene, Plasmid #12254), a bicistronic lentiviral vector
allowing the simultaneous expression of the transgene and EGFP under the control of the
EF1-α promoter.
DD-Akt(WT). Akt(WT) was amplified from mouse cDNA using primers as follows: Fwd
5'-tctagcgcatgcATGAACGACGTAGCCATTGTGAA-3'and Rev 5'-cattatccgcggT
CAGGCTGTGCCACTGGCTGA-3'. The amplicon was inserted 3’ of the DD domain, replacing
YFP, in a pBMN vector using restriction sites Sph1 and SacII to create pBMN-DD-Akt(WT).
Western immunoblotting
Cells were homogenized in 1x cell lysis buffer (Cell Signaling Technology, #9803) with LDS-
sample buffer (Invitrogen) supplemented with 50 mM dithiothreitol and complete mini prote-
ase inhibitor mixture (Roche, #11836170001), or in 1x sample buffer (5x sample buffer: 250
mM Tris-HCl pH 6.8, 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% 2-hydroxy-1-etha-
nethiol). Lysates were boiled at 100˚C for 10–20 min prior to analysis. A total of 20 μg of pro-
teins was loaded per well of 10% or 4–12% Bis-Tris polyacrylamide gels (Invitrogen) and
separated by electrophoresis for 1.5 h at 100 V. Proteins were then transferred onto a nitrocel-
lulose membrane (Bio-Rad) for 1 h 30 min at 40 V. Membranes were blocked with 5% pow-
dered milk in TBS containing 0.1% of Tween 20 (TBST) and incubated overnight at 4˚C with
primary antibodies.
The following primary antibodies were used for Western blotting: rabbit anti-phospho-Akt
(pThr308) (Cell Signaling Technology #13038 [34], #2965 [35]), mouse anti-phospho-Akt
(Thr308) (Cell Signaling Technology #5106 [36]), rabbit anti-phospho-Akt (Ser473) (Cell Sig-
naling Technology #4060 [34]), rabbit anti-pan-Akt (Cell Signaling Technology #4685 [37]),
rabbit anti-phospho-FoxO4 (pS193) (Cell Signaling Technology #9471 [38]), rabbit anti-total
FoxO4 (Cell Signaling Technology #2499 [38]), mouse anti-actin (Sigma #A3853 [39]),
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GAPDH (Abcam #AB9484 [40]), and rabbit anti-Erk1/2 (Santa Cruz Biotechnology, #sc-93
[41]).
Membranes were washed 3 times with TBST and incubated with HRP-conjugated second-
ary antibodies or IRDye secondary antibodies (Li-Cor, goat anti mouse #680LT, goat anti rab-
bit #800CW). After 3 final washes with TBST, blots were incubated with ECL reagents (GE
Healthcare), and chemiluminescent signals were detected by exposure to autoradiography
film, or blots were imaged using a Li-Cor Odyssey CLX imaging system. Films were scanned
using a desktop scanner, and band intensities were determined using ImageJ, or Odyssey
images were analyzed using Image Studio Lite Ver 4.0. For all western blot experiments, inten-
sity data were normalized to ERK1 as loading control. In some experiments we also probed for
EGFP (rabbit anti-GFP (Invitrogen, #A11122) as a control for consistency of transduction effi-
ciency. As shown in S1 Fig, transduction efficiency was similar in replicate PC12 cell cultures
and there was relatively strong concurrence between ERK loading and GFP transfection con-
trols. Comparable results were achieved with transfected HEK293 cells.
Immunofluorescence
Cells were fixed for 12–15 min in 4% paraformaldehyde, washed 3 times with 1x PBS, blocked
with Superblock (Thermo Scientific) supplemented with 0.3% Triton-X for 1 h at room tem-
perature and incubated overnight at 4˚C with primary antibodies. The following primary anti-
bodies were used for immunofluorescence: mouse anti-tyrosine hydroxylase (Millipore,
#MAB318), rabbit anti-tyrosine hydroxylase (Millipore, #AB152), rabbit anti-GFP (Invitrogen,
#A11122), chicken anti-GFP (Invitrogen, #A10262), mouse anti-HA (Cell Signaling Technol-
ogy, #2367), and rabbit anti-phospho-Akt (Thr308) (Cell Signaling Technology, #13038). Cells
were washed 3 times with PBS and incubated with fluorescent secondary antibodies for 1–2 h
at room temperature: AlexaFluor-568 anti-mouse, or anti-rabbit, AlexaFluor-488 anti-chicken,
anti-mouse, or anti-rabbit, and AlexaFluor-350 anti-mouse or anti-rabbit (Invitrogen). For
HEK293 cells grown in multiwell dishes, Hoechst 33328 was added to the first PBS wash, cells
were washed 2 additional times in PBS, and cultures were observed with an inverted fluores-
cence microscope. For ventral midbrain dopaminergic neurons grown on glass coverslips,
after 3 final washes with PBS, coverslips were mounted on slides with Vectashield mounting
medium containing DAPI for nuclear staining (Vector Laboratories). Images were acquired
using an Olympus inverted or upright fluorescent microscope equipped with a digital camera
and Cellsens software.
Animal use
This study was carried out in strict accordance with the recommendations in the Guide for the
Use of Laboratory Animals of the National Institutes of Health. All animal procedures,
described herein were approved by the Columbia University Animal Care and Use Commit-
tee, IACUC (protocols AC-AAAR7401 and AC-AAAR8404). All viral injections were carried
out using ketamine/xylazine anesthesia and all efforts were made to ameliorate animal suffer-
ing. Euthanasia was carried out by CO2 inhalation followed by cervical dislocation (mice) or
thoracotomy (rats) consisent with the recommendations of the Panel on Euthanasia of the
American Veterinary Medical Association.
Preparation and injection of viral vectors
Lentivirus. All viral plasmids were obtained from Addgene. The transfer plasmid for
overexpression was pWPI, which encodes transgene-IRES-GFP under the control of the
EF1-alpha promoter. Viruses were prepared in HEK293T cells using second-generation
Conditionally-inducible Akt
PLOS ONE | https://doi.org/10.1371/journal.pone.0197899 June 19, 2018 5 / 22
packaging plasmids pMD2G and psPAX2 (obtained from Addgene) through calcium phos-
phate transfection. Lentiviral supernatants were collected twice (48 h and 72 h after transfec-
tion) and concentrated using Lenti-X concentrator (Clontech, #631231) according to the
manufacturer’s protocols, resuspended in PBS, and stored at -80˚C.
For transduction of neuronal cultures, 5–10 MOI were added directly in the medium of
neuronal PC12 cells, primary cortical neurons, or ventral midbrain dopaminergic neurons.
Transduced neurons were analyzed by western blot or immunofluorescence after 5–7 days.
Adeno-associated virus. All vectors used for these studies were AAV1 serotype. For AAV
vector generation, the DD-HA-Akt(E40K) gene was modified to incorporate a Flag-encoding
sequence (5’-GACTACAAAGACGATGACGACAAA-3’) at the 3’ end of the gene (denoted as
DD-Akt(E40K)-Flag) and inserted into an AAV packaging construct that utilizes the chicken
β-actin promoter and contains a 30 WPRE (pBL) as previously described [20]. Similarly, an
Akt(E40K) insert with no DD domain was modified to incorporate a Flag-encoding sequence
and inserted into an AAV packaging construct (pBL). All nucleotide sequences in the AAV
packaging constructs were confirmed before AAV production. AAVs were produced by the
University of North Carolina Vector Core. The viral titer of AAV-DD-Akt(E40K)-Flag was
2.3 x 1011 viral molecules/ml and those of AAV-Akt(E40K) was 4.9 x 1012 viral molecules/ml.
For AAV injections, adult (8 week) male C57BL/6 mice were obtained from Charles River
Laboratories, Wilmington, MA. Mice were anesthetized with ketamine/xylazine solution and
placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA) with a mouse adapter. For
intranigral injections, the tip of a 5.0 μl syringe needle (26S) was inserted to stereotaxic coordi-
nates AP: −0.35 cm; ML: +0.11 cm; DV: −0.37 cm, relative to bregma. For intrastriatal injec-
tions, the tip of a 5.0 μl syringe needle (26S) was inserted to stereotaxic coordinates AP: +0.09
cm; ML: +0.22 cm; DV: -0.25 cm relative to bregma. Viral vector suspension in a volume of
2.0 μl was injected at 0.1 μl/minute over 20 minutes.
Oral Trimethoprim (TMP) administration
Mice were given freshly prepared 1.31 mg/ml TMP-lactate (ChemImpex International), which
is equivalent of 1 mg/ml TMP, in their drinking water. TMP solutions were covered with alu-
minum foil to protect from light exposure and changed every 2–4 days for 3 weeks.
Immunohistochemical staining of brains
For Flag immunostaining, mice were perfused with 0.9% NaCl for 5 min followed by 4% para-
formaldehyde in 0.1 M phosphate buffer for 10 min. Perfused mouse brains were postfixed for
24 h, cryoprotected in 20% sucrose overnight, and then rapidly frozen by immersion in isopen-
tane on dry ice. A complete set of serial sections was then cut through the SN or striatum at
30 μm. For SN sections, beginning with a random section between 1 and 4, every fourth sec-
tion was chosen for immunostaining. For striatal sections, beginning with a random section
between 1 and 6, every sixth section was chosen for immunostaining. Chosen sections were
treated with Mouse-on-Mouse Blocking Reagent (Vector Labs) and processed free-floating
with a mouse monoclonal anti-Flag antibody (Sigma) at 1:1000. Sections were incubated with
biotinylated anti-mouse IgG (Vector Labs), followed by ABC (Vector Labs). After immuno-
peroxidase staining, sections were mounted, dehydrated, and analyzed for neuronal counts
using stereological analysis.
Stereological analysis
To determine the number of Flag-positive neurons in the SN or the striatum, the entire region
of interest was defined within the StereoInvestigator program (MicroBrightField, Williston,
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VT). A fractionator probe was established for each section. The number of Flag-positive neu-
rons in each counting frame was determined by focusing down through the section, using
100x objective under oil, as required by the optical dissector method. Our criterion for count-
ing an individual Flag-positive neuron was the presence of its nucleus either within the count-
ing frame, or touching the right or top frame lines (green), but not touching the left or bottom
lines (red). The total number of Flag-positive neurons for each brain was then determined by
the StereoInvestigator program.
Statistical analysis
All statistical analyses were performed with GraphPad Prism 6 software. Simple comparisons
of two experimental groups were performed using t-tests. Multiple comparisons of more than
two experimental groups were performed using two-way ANOVA and Tukey’s multiple com-
parisons test. The threshold of significance was set at α = 0.05 for all experiments.
Results
Expression and inducibility of DD-Akt(E40K)
To create an inducibly active Akt system, we genetically fused DHFR-derived DD to the N-ter-
minus of HA-tagged constitutively active Akt(E40K) (Fig 1A). The Akt(E40K) construct used
here consists of the mouse Akt1 isoform with a glutamate to lysine substitution at amino acid
40, located within the PH domain. This substitution is analogous to the reported star mutation
in the PH domain-containing Bruton tyrosine kinase and reported to enhance the binding
specificity of Akt to phospholipids at the plasma membrane, thus leading to higher basal activ-
ity that is sufficient to replicate multiple biological effects associated with Akt activation [42–
44]. In principle, this strategy would permit the accumulation of active DD-Akt(E40K) after
treatment with the stabilizing ligand, TMP (Fig 1B).
As an initial means to validate the inducibility of the DD-Akt(E40K) fusion protein by
TMP, an expression vector for bicistronic expression of both HA-tagged DD-Akt(E40K) and
GFP was created and transfected into HEK293 cells. After 24 hr of TMP (10 μM) treatment,
we observed markedly increased levels of HA immunostaining within cells in a distribution
similar to that of GFP, indicating stabilization and accumulation of DD-Akt(E40K) (Fig 1C).
There was also a low, but detectable level of HA staining in cultures transfected with DD-Akt
(E40K) but untreated with TMP compared to cultures transfected with an empty vector
(pWPI), indicating that there is a basal level of DD-Akt(E40K) expression without TMP.
As discussed above, Akt(E40K) has altered phospholipid binding activity leading to
increased plasma membrane recruitment, which promotes its phosphorylation at Ser473 and
Thr308 and consequent activation. To determine whether TMP treatment would also lead to
accumulation of activated Akt, HEK293 cells were transfected as above, treated with 10 μM
TMP for 24 hr, and processed for immunofluorescence staining of GFP and pAkt-T308 (Fig
1D). We observed robust induction of phosphorylated Akt staining within transfected cells
after TMP treatment, thus paralleling the increased expression of stabilized DD-Akt(E40K)
(Fig 1C).
The induction of total and activated Akt was also apparent when cells were processed for
western immunoblotting (Fig 1E; see S2A–S2C Fig for uncropped blots with mol wt markers).
With the presence of the DHFR-derived DD domain, DD-Akt(E40K) is easily distinguished
from endogenous Akt in western blots due its higher molecular weight. The average fold-
induction levels from multiple independent experiments were about 2.5-fold for total Akt and
for pAkt-(pS473), and nearly 5-fold for pAkt(pT308) (Fig 1F). It should be noted that fold-
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induction was variable across experiments primarily due to differences in the detectable back-
ground levels of DD-Akt(E40K) in TMP-untreated cultures.
Because the E40K mutation of Akt increases its membrane affinity, it was conceivable that
this would interfere with its degradation and, therefore, inducibility of DD-Akt(E40K). To
assess this, we prepared a DD-Akt(WT) construct and compared its expression and inducibil-
ity with that of DD-Akt(E40K) by western immunoblotting of total and phosphorylated Akt
forms (S3 Fig). There were no significant differences in the expression of these forms in the
absence of TMP nor induction of total Akt in presence of the drug. As anticipated by its
enhanced membrane association, induction of the activated phospho-Akt proteins was signifi-
cantly higher for DD-Akt(E40K) compared with DD-Akt(WT).
Fig 1. Generation and characterization of an inducible DD-Akt(E40K). (A) Design and schematic structure of the
DD-Akt(E40K) fusion protein. (B) Scheme depicting mechanism of predicted induction of DD-Akt(E40K) in presence
of TMP. (C) Induction of DD-Akt(E40K) by TMP in HEK293 cells as visualized by immunostaining. Cultures were
transfected with a bicistronic IRES expression vector (pWPI) expressing the DD-Akt(E40K) fusion protein and eGFP,
treated with or without 10 μM TMP for 24 hr and then fixed for immunofluorescence staining. GFP staining indicates
cells expressing the vector while HA immunostaining reveals expression of the DD-Akt(E40K) fusion protein. Scale
bars indicate 100 μm. (D) Induction of phosphorylated DD-Akt(E40K) by TMP in HEK293 cells as visualized by
immunostaining. Cultures and treatment were as in (C) except that immunostaining was for pAkt(pT308) to visualize
active Akt. (E) Western immunoblot analysis of total and phosphorylated DD-Akt(E40K) induction by TMP in
HEK293 cells. Treatment was as in (C) with the addition that some samples were derived as indicated from cultures
transfected with pWPI vector expressing only eGFP. Arrows show positions of endogenous (endo-) and DD-Akt
forms. Blots were probed for total Akt and for pAkt(pT308) and pAkt(pS473). ERK 1 and actin served as loading
controls. (F) Average fold induction of indicated DD-Akt forms by TMP treatment. HEK293 cultures were prepared as
above and quantification of expression determined by western immunoblotting and quantification of relative band
densities by ImageJ as in Methods. N = 8–9 experiments each, with duplicate or triplicate wells per condition. Graph
shows means with SEM. p< 0.01, p< 0.001, paired t-test +TMP vs.–TMP levels.
https://doi.org/10.1371/journal.pone.0197899.g001
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We also evaluated the possibility that the presence of an additional DD domain will reduce
basal expression of the Akt(E40K) fusion protein in absence of TMP by promoting more effi-
cient degradation. In designing such a construct, we further considered that the close proxim-
ity of the DD-domain to the much larger Akt protein might hinder degradation. Our initial
DD-Akt(E40K) construct contains an Arg-Ala-Cys linker between the DD domain and the
HA-tag. We therefore assessed various constructs (S4 Fig) with a second DD-domain and gly-
cine linker sequences (Gly-Gly-Gly-Gly-Ser)1-2 (G4S)1-2 with the potential for enhanced flexi-
bility as previously described (Iwamoto et al., 2010). We found that such constructs did not
undergo substantially different levels of expression or induction by TMP compared with
DD-Akt(E40K), with the only apparent significant difference being an approximate 60%
increase in induction of (DD-G4S)2-pAkt(E40K-pT308) by TMP (S4 Fig).
Given that the E40K mutation did not interfere with induction of the total protein by TMP
and enhanced induction of the active forms, and that the modified constructs did not confer
substantially enhanced levels of TMP induction, subsequent experiments were carried out
with the initial DD-Akt(E40K) construct.
DD-Akt(E40K) is inducible in a neuronal background
The inducibility of DD-Akt(E40K) was further tested in a different cell type, neuronally-differ-
entiated PC12 cells. These have been widely used to model neurons and have been employed
in numerous studies of potential relevance to neurotrophic factor signaling and to PD and
other neurodegenerative disorders [18, 29, 32, 45]. The cells were transduced with either
empty or DD-Akt(E40K)-expressing lentiviral vectors, treated with or without 10 μM TMP for
24 hr, and then processed for immunoblotting to determine levels of DD-Akt(E40K) expres-
sion (Fig 2A and 2B). Here again, induction by TMP was evident with mean levels of increase
of 2.6-fold for DD-pAkt(E40K-pT308), 3.6-fold for DD-pAkt(E40K-pS473) and 11.9-fold for
total DD-Akt(E40K). We also compared the levels of DD-pAkt(E40K) reached after TMP
induction to those of endogenous pAkt (Fig 2C). This revealed that both DD-pAkt(E40K-
pT308) and DD-pAkt(E40K-pS473) reached levels comparable to those of the corresponding
endogenous proteins. Although transduction efficiency was not assessed in all experiments,
efficiency was approximately 75% for our experimental conditions as measured by the propor-
tion of GFP-expressing cells.
The inducibility of DD-Akt(E40K) also was assessed in primary cultures of rat cortical neu-
rons. Four days after infection with lentivirus expressing GFP alone or DD-Akt(E40K) and
GFP, the cultures were treated for 24 hr with or without 10 μM TMP and evaluated by western
immunoblotting for levels of total and phosphorylated (at S473) Akt. There was an approxi-
mate 2-fold induction by TMP of DD-pAkt(E40K-pS473) and a 3.5-fold increase of total
DD-Akt(E40K) (Fig 2D and 2E). Assessment of GFP expression indicated an infection effi-
ciency of about 50% of the neurons. Taking this into consideration, the data indicate that the
levels both of total and phosphorylated DD-Akt reached after induction were comparable or
greater than the endogenous levels of the corresponding proteins (Fig 2D).
DD-Akt(E40K) inducibility is dose-responsive and reversible
One of the potential advantages of the DD system is its dose-responsive inducibility by the sta-
bilizing ligand [22]. To assess this for our construct, HEK293 cells were transiently transfected
with DD-Akt(E40K) expression vector and then treated with doses of TMP ranging from 10
nM to 100 μM for 24 hr. The induction of DD-Akt(E40K) and DD-pAkt proteins was dose-
responsive to TMP, reaching half-maximal induction by approximately 30 nM (Fig 3A and
3B). We also examined the kinetics of induction and reversal of DD-Akt induction by TMP.
Conditionally-inducible Akt
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DD-Akt(E40K)-transfected HEK293 cells were assessed by western blotting at different times
after either TMP addition or washout. Induction of DD-Akt(E40K) by TMP was evident by 6
hr and appeared to continue to accumulate up to at least 24 hr. (Fig 3C). To assess reversal,
transfected cells were treated with 10 μM TMP for 24 hr, washed free of the drug and analyzed
by western immunoblotting at various time points (Fig 3D). This showed a nearly linear
decrease of DD-Akt(E40K) levels with approximately 30 hr required for half reversal of
induction.
DD-Akt(E40K) induction leads to elevated phosphorylation of downstream
substrate FoxO4
To validate that the induced DD-Akt(E40K) fusion protein maintains its function as a kinase,
we investigated the effect of its induction on a purported Akt substrate, the transcription factor
FoxO4 [1]. HEK293T cells were transfected with DD-Akt(E40K) expression vector, treated
with or without 10 μM TMP for 24 hr, and analyzed by western immunoblotting for levels of
FoxO4 phosphorylated at the phosphorylation site linked to Akt-dependent phosphorylation,
S193 (pFoxO4) (Fig 4A and 4B). This revealed an approximate doubling of pFoxO4 levels after
DD-Akt(E40K) induction with TMP. In contrast, there was no significant elevation of pFoxO4
Fig 2. DD-Akt(E40K) is inducible in a neuronal context. (A) Western immunoblot analysis of DD-Akt(E40K)
induction by TMP in neuronal PC12 cells. Neuronal PC12 cells were infected as indicated with a lentiviral vector
expressing either eGFP alone (pWPI) or the DD-Akt(E40K) fusion gene and eGFP. Four days post-infection, cells were
treated with or without 10 μM TMP as indicated for 24 hr and then harvested for western immunoblotting. Blots were
probed as indicated for total Akt, pAkt(pT308), pAkt(pS473) and GAPDH (loading control). A representative blot is
shown. (B) Average fold induction of DD-Akt forms by TMP treatment in neuronal PC12 cultures. N = 4–6
independent experiments with duplicate or triplicate wells per condition. Graph shows means with SEM. p 0.05,
paired t-test, +TMP vs.–TMP levels. (C) The relative expressions of induced DD-pAkt(E40K) and endogenous pAkt
levels in neuronal PC12 cells quantified and calculated as a percent ratio. (D) Western immunoblot analysis of total
and phospho-S473 forms of DD-Akt(E40K) induction by TMP in cultured rat cortical neurons. Cultured rat cortical
neurons were infected as indicated with a lentiviral vector expressing either eGFP alone (pWPI) or the DD-Akt(E40K)
fusion gene and eGFP. Four days post-infection, cells were treated with or without 10 μM TMP as indicated for 24 hr
and then harvested for western immunoblotting. Blots were probed as indicated for total Akt, pAktT308, pAktS473
and GAPDH (loading control). Assessment of GFP expression indicated an infection efficiency of about 50% of the
neurons. A representative blot is shown. (E). Average fold induction of total and DD-pAkt(E40K-pS473) by TMP
treatment in cortical neuron cultures. N = 2 samples per condition. Values are means with SEM. p<0.05, p<0.01,
unpaired t-test, +TMP vs -TMP.
https://doi.org/10.1371/journal.pone.0197899.g002
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after DD-Akt(E40K) transfection in the absence of TMP treatment, thus indicating that basal
expression levels of DD-Akt(E40K) were insufficient to significantly elevate FoxO4 phosphor-
ylation (pS193). Additionally, under the various experimental conditions, there was no change
of total FoxO4 levels (Fig 4A).
TMP-mediated induction of DD-Akt(E40K) protects against cell death
We next examined whether DD-Akt(E40K) induction promotes physiologic responses. Undif-
ferentiated (NGF-untreated) PC12 cells rely on the presence of serum in the medium for sur-
vival. When serum is removed from the medium, the cells undergo apoptosis that can be fully
reversed by the addition of NGF [46]. This action of NGF appears to be dependent on Akt sig-
naling [47]. We therefore used this model to provide a functional readout for TMP-induced
DD-Akt(E40K) induction.
PC12 cells were transduced with lentiviral vectors to co-express DD-Akt(E40K) and GFP
(or empty vector and GFP) and subsequently treated with 10 μM TMP for 24 hr. Cells were
washed free of serum and replated in serum-free medium under continued presence or
absence of TMP. Cultures infected with empty vector and treated with NGF were included as
positive controls for normalization. Counts of surviving cells were performed after 16–24 hr of
serum deprivation (Fig 4C). Under these serum-free conditions and when compared with
NGF-treated cultures, a mean of 57% ± 2% of cells survived in cultures transduced with empty
vector and not treated with NGF. In contrast, survival in cultures transduced with DD-Akt
Fig 3. DD-Akt(E40K) induction is dose-responsive to TMP treatment and reversible. (A) Western immunoblotting
analysis of dose-response of DD-Akt(E40K) induction by TMP. HEK293 cells were transfected with eGFP-only
expressing vector (EV) or DD-Akt(E40K) fusion protein expression vector and treated with indicated doses of TMP
for 24 hr before analysis by western immunoblotting with the indicated probes. (B) Quantification of DD-Akt(E40K)
induction (as determined by western immunoblotting) by various doses of TMP. Values means with SEM. N = 3–4
independent experiments. (C) Time course of DD-Akt(E40K) induction by TMP. HEK293 cells were transfected with
DD-Akt(E40K) expression vector, treated with 10 μM TMP for the indicated times and then assessed for total DD-Akt
(E40K) levels by western immunoblotting as in (A). Values are means with SEM. N = 2–4 independent experiments.
(D) Reversal of DD-Akt(E40K) induction after TMP washout. HEK293 cultures transfected with DD-Akt(E40K) as
above were treated with 10 μM TMP for 24 hr, washed free of TMP and harvested for western immunoblotting at the
indicated time points. Total DD-Akt(E40K) levels were determined by western immunoblotting as in (A). Data shown
are from one experiment.
https://doi.org/10.1371/journal.pone.0197899.g003
Conditionally-inducible Akt
PLOS ONE | https://doi.org/10.1371/journal.pone.0197899 June 19, 2018 11 / 22
Fig 4. Induction of DD-Akt(E40K) leads to substrate phosphorylation and neuroprotection. (A) Induction of
DD-Akt(E40K) promotes phosphorylation of the putative Akt substrate FoxO4 on pS193. HEK293 cells were
transfected with vector expressing eGFP alone (EV) or DD-Akt(E40K) and eGFP, treated with or without 10 μM TMP
for 24 hr, and then harvested and analyzed by western immunoblot analysis for the indicated proteins. Total FoxO4
was analyzed on a separate immunoblot and is shown with its own loading controls. Numbers below the bands
indicate relative densities (determined by ImageJ), normalized to corresponding ERK1 loading control. (B)
Quantification of western immunoblotting data for effect of DD-Akt(E40K) induction on pFoxO4(pS193) levels.
Experiments were performed and quantified as in (A). Values are given as mean fold-induction of pFoxO4(pS193)
levels under the indicated conditions with SEM. N = 9 independent experiments (7 experiments with no serum
present, 2 experiments with serum present). p<0.01 compared with DD-Akt(E40K)—TMP condition, #p<0.05
compared with empty vector (EV) condition, one-way ANOVA. (C) DD-Akt(E40K) induction protects against serum
deprivation. Naïve (NGF-untreated) PC12 cells were infected with lentiviral vectors for overexpression of DD-Akt
(E40K) and eGFP or eGFP alone (EV). Four-five days after infection, cultures expressing DD-Akt(E40K) were pre-
treated with or without 10 μM TMP for 24 hr and then extensively washed and replated with serum-free medium with
or without the continued presence of TMP. EV cultures were deprived of serum in similar fashion and treated either
with or without NGF (100 ng/ml). After 16–24 hr of serum deprivation, cells were lysed for quantification of viable
nuclei to measure survival. Average infection efficiency was 60%. Data were normalized to survival in NGF-treated
cultures and are expressed as means with SEM. p< 0.05, n.s. vs. EV-NGF; 2-way ANOVA. N = 2–3 independent
experiments. (D) Induction of DD-Akt(E40K) protects against the PD mimetic toxin MPP+. Neuronal PC12 cells were
infected with lentiviruses for overexpression of DD-Akt(E40K) and eGFP or eGVP alone (EV). Four to five days after
infection cultures were pre-treated with or without 10 μM TMP for 24 hr before addition of 0.25 mM MPP+. After 18–
24 hr of MPP+ treatment, cells were lysed for quantification of viable nuclei to measure survival. Values are means
with SEM and were normalized to cell numbers in cultures infected with EV and not exposed to MPP+. p< 0.01
vs.–TMP; ##p< 0.01 vs. EV; n.s. vs. EV; 2-way ANOVA. N = 3 independent experiments. (E) Induction of DD-Akt
(E40K) protects against the PD mimetic toxin 6-OHDA. Neuronal PC12 cell cultures were established and treated and
analyzed as above, except that treatment was with 6-OHDA. Values are means with SEM. p< 0.001 vs.–TMP;
p< 0.05 vs.–TMP; ### p< 0.001 vs. Empty Vector; n.s. vs. Empty Vector; 2-way ANOVA. N = 3 independent
experiments. (F) TMP does not protect from 6-OHDA in absence of DD-Akt(E40K). Neuronal PC12 cells were
pretreated with or without 10 μM TMP for 24 hr before addition of 100 μM or 150 μM 6-OHDA and assessed as above
for survival 18–24 hr later. Values are means with SEM. There were no significant effects of TMP on cell survival under
any conditions, 2-way ANOVA. n = 2 independent experiments with 3 replicates per condition per experiment.
https://doi.org/10.1371/journal.pone.0197899.g004
Conditionally-inducible Akt
PLOS ONE | https://doi.org/10.1371/journal.pone.0197899 June 19, 2018 12 / 22
(E40K) and treated with TMP averaged 92% ± 13% of survival reached with NGF. Cultures
transduced with DD-Akt(E40K) but not induced with TMP treatment had a mean survival
rate of about 61% ± 8%, which was not significantly different from that in control NGF-
untreated cultures. Taken together, these findings indicate that induction of DD-Akt(E40K)
by TMP treatment is sufficient to protect PC12 cells from serum deprivation-induced apopto-
sis to a degree similar to that achieved with NGF, and that the level of DD-Akt(E40K)
expressed without induction is insufficient to provide significant protection.
Induced DD-Akt(E40K) protects against cell death evoked by MPP+ and
6-OHDA
6-hydroxydopamine (6-OHDA) has been widely used in in vitro and in vivo models of PD as
have 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite 1-methyl-
4-phenylpyridinium (MPP+) [48]. Both neurotoxins cause selective degeneration of dopami-
nergic neurons, and MPP+ and 6-OHDA can induce degeneration of neuronal PC12 cells, pro-
viding an in vitro model that is potentially relevant to PD [49, 50]. Prior work indicates that
activation of Akt protects neurons from these toxins both in vitro and in vivo [18, 51]. To
determine whether DD-Akt(E40K) can inducibly protect neuronal PC12 cells from these PD
mimetic toxin insults, we infected cultures with DD-Akt(E40K) expressing lentivirus or with
an empty virus and then pretreated with or without 10 μM TMP for 24 hr before exposure to
0.25 mM MPP+, or 100–150 μM 6-OHDA for 18–24 hr. The numbers of surviving cells were
then determined under each condition. As shown in Fig 4D and 4E, there was significant pro-
tection in both models in TMP-treated cultures expressing DD-Akt(E40K). In contrast, there
was no significant protection for corresponding cultures not treated with TMP, indicating that
the basal expression of DD-Akt(E40K) was insufficient to impact survival rates. The transduc-
tion efficiency for these cultures was approximately 75%, as determined by immunofluores-
cence staining of GFP-positive cells. If a correction is made for incomplete transduction, the
survival with TMP-induced DD-Akt(E40K) would be 95% in the MPP+ toxin model, 96% at
the lower dose of 6-OHDA, and 81% at the higher dose of 6-OHDA.
To verify that the observed protection after TMP treatment was not due to the drug alone,
we pre-treated uninfected neuronal PC12 cell cultures with or without 10 μM TMP for 24 hr
and then assessed survival after 18–24 hr of exposure to 100 or 150 μM 6-OHDA. As shown in
Fig 4F, TMP alone showed no significant effect on cell death in this model.
Inducibility of DD-Akt(E40K) appears to be region-specific in vivo
The observations that induction of DD-Akt(E40K) is protective in in vitro PD models and that
virally-delivered myr-Akt protects dopaminergic neurons of the substantia nigra in a
6-OHDA model [20] prompted us to examine whether DD-Akt(E40K) might be suitable as an
inducible neuroprotective agent for dopaminergic neurons in living animals. Towards this
end, we tested the inducible expression of DD-Akt(E40K) in two regions of the mouse brain:
the SNpc and striatum. A Flag-tagged DD-Akt(E40K) construct was packaged into an adeno-
associated virus serotype 1 (AAV1) vector that selectively infects neurons [20] and stereotacti-
cally delivered unilaterally to the SNpc or striatum of adult male C57BL/6 mice following pre-
viously described procedures. We confirmed in HEK293 cells that the Flag-tagged construct
was inducible similarly to the HA-tagged construct (data not shown). Because TMP passes the
blood brain barrier [52], the drug was administered in the drinking water, beginning at 3
weeks post-injection to allow for expression of the transgene. Previous literature has described
the induction of DD-fusion proteins in the rat striatum with a TMP dose range of 0.1–0.5 mg/
ml, administered in the drinking water for 3 weeks [22, 26, 27]. In our study, the mice were
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treated for 3 weeks with or without 1 mg/ml TMP in the drinking water, and then their fixed
brains were processed for Flag immunostaining as a direct readout of DD-Akt(E40K)-Flag
expression (Fig 5A).
Visible observation revealed no evident difference in numbers or staining intensity of Flag-
stained neurons in the SNpc of mice with or without TMP treatment (Fig 5B). Stained sections
Fig 5. Regional inducibility of DD-Akt(E40K) in the mouse brain. (A) Scheme of experimental design. Adult
C57BL/6 mice were subjected to unilateral AAV-DD-Akt(E40K)-Flag injections into the SNpc or striatum. At 3 weeks
post-viral injection, the mice were treated with or without 1 mg/ml TMP in their drinking water for 3 weeks and then
their brains were harvested and processed for Flag immunostaining. (B) Representative images of Flag immunostained
neurons in the SNpc of both TMP-untreated and TMP-treated mice. (C) Stereological quantification of total numbers
of Flag-stained neurons in the SNpc of mice treated as above with or without TMP. The data represent total Flag-
positive neuron numbers in the SNpc per mouse. Mean values are shown with SEM. n = 7 mice for -TMP, n = 6 mice
for +TMP. n.s., determined by unpaired t-test. (D) Representative images of Flag immunostaining in the striatum of
both TMP-untreated and TMP-treated mice. Staining in the medial striatum is outlined by a black rectangle and
shown at higher magnification in the inset; the external capsule (EC) and needle track (NT) staining is indicated by
brackets. (E) Stereological quantification of total numbers of Flag-stained neurons in the striata of mice treated as
above with or without TMP. The data represent total Flag-positive neuron numbers in the entire striatum per mouse.
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were subsequently analyzed stereologically in a blinded manner to determine total numbers of
Flag-positive neurons in the SNpc of control and TMP-treated mice (Fig 5C). There was no
statistically significant difference in the numbers of Flag-positive neurons between the treat-
ment groups, indicating that expression of DD-Akt(E40K)-Flag in the mouse SNpc is not
induced after oral administration of TMP.
To explore the possibility of a region-dependent effect on the induction of DD-Akt(E40K),
we next examined the inducibility of the construct in the striatum of adult male mice, following
the same TMP treatment protocol (Fig 5A). As noted above, past work has described control of
DD-fusion proteins in rodent striatum by oral TMP administration [22, 26–28]. Although both
treatment groups exhibited Flag-positive neurons, indicating that DD-Akt(E40K)-Flag was
expressed, the staining in non TMP-treated mice appeared to be limited to the needle track and
along the external capsule of the striatum (Fig 5D). In contrast, Flag staining in TMP-treated
mice appeared to be more diffuse along the needle track in all mice and show a distinct area of
staining in the medial striatum in four of seven mice. Neither of these features was observed in
TMP-untreated mice. To quantify the effect of TMP treatment, sections were stereologically
analyzed in a blinded manner for total numbers of Flag-positive cells within each striatum (Fig
5E). We found a statistically significant difference between treatment groups with TMP-
untreated mice exhibiting a mean of 13,238 ± 2602 Flag-stained neurons per striatum and
TMP-treated mice exhibiting a mean of 24,009 ± 2984 Flag-stained neurons (p = 0.03). This
translates to a 1.8-fold increase in DD-Akt(E40K) expression after TMP treatment.
Cell type-dependent induction of DD-Akt(E40K) in ventral midbrain
cultures
The results presented above suggest that there may be region- and/or cell-type specific induc-
tion of DD-Akt(E40K). To investigate this further in a system relevant to dopaminergic neu-
rons and PD, we examined the inducibility of DD-Akt(E40K) in primary cultures of the
ventral midbrain. Ventral midbrain neurons were isolated and cultured as previously
described [31] from P0-P3 rats and infected with lentivirus expressing both HA-tagged
DD-Akt(E40K) and GFP. Six to 10 days post-infection, the cultures were treated with or with-
out 10 μM TMP for 4 days and triple-stained for tyrosine hydroxylase (TH) to identify DA
neurons, GFP to identify transduced cells, and HA to identify levels of DD-Akt(E40K) (Fig
6A). Neurons exhibiting dual fluorescence signals for both GFP and TH were quantified for
HA signal intensity. The results show a significant increase of 1.9-fold ± 0.2 (p< 0.005 vs.-
TMP) in HA fluorescence intensity for DA neurons treated with TMP compared with those
without TMP exposure (Fig 6B). This indicates that under our culture conditions, DA neurons
undergo TMP-dependent induction of DD-Akt(E40K).
In addition to TH+ neurons, ventral midbrain cultures contain substantial numbers of TH-
neurons. These were also infected by our lentivirus and their expression of DD-Akt(E40K)
appeared to be TMP-responsive (Fig 6A). Quantification of the HA signal in TH- neurons
(randomly chosen in the same cultures in which the HA signals of TH+ neurons were quanti-
fied) revealed a 6-fold induction of DD-Akt(E40K) by TMP (Fig 6B). To better understand the
basis for this more than 3-fold higher level of induction in TH- compared with TH+ neurons,
we compared the levels of HA fluorescence intensity in the two populations. This revealed that
while the mean level of signal reached after TMP treatment was similar for TH+ and TH- neu-
rons, the level of expression without TMP was about 3-fold higher in TH+ neurons (Fig 6B).
Because the expression of DD-fused proteins in absence of TMP is regulated by proteasomal
degradation, these findings suggest that dopaminergic neurons in our cultures were substan-
tially less efficient in protein turnover than their non-dopaminergic neighbors.
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Discussion
The present study describes the generation and characterization of a conditionally inducible,
active form of Akt1, DD-Akt(E40K). To achieve this, we used the TMP-regulated destabilizing
domain approach initially described by the laboratory of Dr. Wandless [22]. This technique
has been used for a variety of applications both in vitro and in vivo [23–28, 53, 54]. Our find-
ings indicate that DD-Akt(E40K) is: robustly induced by the ligand TMP; enzymatically active
with inducibly enhanced phosphorylation of the known Akt substrate FoxO4; biologically
active with promotion of serum-free cell survival and protection from the PD-mimetic toxins
6-OHDA and MPP+. Moreover, induction was observed in a range of cultured cells including
human 293 cells, undifferentiated and differentiated rat PC12 cells, rat cortical neurons and
ventral midbrain dopaminergic and non-dopaminergic neurons. We further found induction
in vivo in mouse striatal cells. Using cultured cells, we observed that induction was dose-
responsive and reversible. Moreover, expression of DD-Akt(E40K) and its phosphorylated
forms was easily detectable and quantifiable by western immunoblotting. Addition of HA or
FLAG tags permitted visual detection of the protein by immunostaining.
One of the potentially attractive features of the destabilizing domain approach is that the
DD-fused protein is rapidly degraded in absence of the TMP ligand, thus providing a very low
Fig 6. Differential induction of DD-Akt(E40K) within ventral midbrain cultures. (A) DD-Akt(E40K) induction in
ventral midbrain cultures. Ventral midbrain cultures were infected with a lentiviral vector expressing DD-Akt(E40K)
and eGFP. 6–10 days post-infection, cultures were treated with or without 10 μM TMP for 4 days and then processed
for immunofluorescent staining of tyrosine hydroxylase (TH) to identify dopaminergic neurons, eGFP to identify
infected cells, and HA to reveal DD-Akt(E40K). Scale bar indicates 50 μm. (B) HA fluorescence intensity was measured
in infected (GFP+) neurons using ImageJ. Dopaminergic vs. non-dopaminergic cells were identified by TH staining.
Values are mean fluoresence intensity in arbitary units (A.U.) with SEM. n = 7–8 TH+ neurons measured for each
condition, 12–14 non-TH neurons measured for each condition. p< 0.05: TH, -TMP vs. + TMP; p< 0.0001:
non-TH, -TMP vs. + TMP; #p< 0.05: TH, -TMP vs. non-TH, -TMP, 2-way ANOVA.
https://doi.org/10.1371/journal.pone.0197899.g006
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basal level of expression. This has provided impressive levels of induction [22]. In the present
study, we observed readily detectable levels of total and phosphorylated DD-Akt(E40K)
expression in absence of TMP for each of the cultured cell types that we studied. While there
was consistent induction with TMP, the fold-induction observed reflected the -TMP back-
ground, providing an induction range of about 2-10-fold for total DD-Akt(E40K) and about
2-5-fold for p-DDAkt(E40K), depending on cell type. As described above, adding a second
DD domain or manipulating linker configuration did not appreciably reduce expression in
absence of TMP.
Because the level of endogenous Akt is not altered in DD-Akt(E40K)-transduced cells, we
were also able to compare the non-induced and induced levels of the fusion protein to expres-
sion of endogenous Akt. This revealed some degree of variation with cell type. For 293 cells,
the basal levels of total DD-Akt(E40K) were approximately twice those of the endogenous pro-
tein and reached 3-5-fold higher levels than the endogenous Akt after TMP treatment. In con-
trast, for neuronal PC12 cells and cortical neurons, total DD-Akt(E40K) was substantially less
(approximately 1/3-1/2) when compared with endogenous protein without TMP, and reached
levels that were 1-2-fold (cortical neurons) or about 3-fold higher (PC12 cells) to endogenous
Akt after TMP treatment. In both neuronal cell types, basal phospho-DD-Akt(E40K) levels
were substantially below those of endogenous p-Akt, and after induction reached levels
approximately double those of endogenous p-Akt. These observations are consistent with our
findings that DD-Akt(E40K) was able to protect PC12 cells from serum deprivation and PD-
mimetic toxins after induction with TMP.
The ability of induced DD-Akt(E40K) to promote survival in different neuronal back-
grounds suggested its potential application for prevention of neurodegeneration in vivo. Par-
kinson’s disease is a particularly relevant target. Affected dopaminergic neurons in the disease
show greatly diminished levels of p-Akt [18, 19] while over-expression of myristoylated Akt
provides profound protection of dopaminergic cell bodies and axons in a mouse model of PD
[20, 21]. Such observations suggested that a tunable and reversible Akt expression system
could be of therapeutic value in preventing dopaminergic neuron degeneration in PD. How-
ever, our findings suggest that at least in the mouse substantia nigra, DD-Akt(E40K) is not
induced by TMP. This contrasted with our finding of inducibility in the striatum. Several
other groups have reported induction of DD-linked proteins in the striatum with TMP [27,
28], and these outcomes, in agreement with our own findings, suggest that failure of induction
in the substantia nigra is not due to an experimental issue, but rather to the cellular context.
One possible reason for the lack of detectable induction of DD-Akt(E40K) in the substantia
nigra might be a relatively high level of basal expression in absence of TMP. This possibility is
supported by our in vitro studies in which dopaminergic midbrain neurons displayed a consid-
erably higher basal level of DD-Akt(E40K) expression (and, as a result, lower induction) com-
pared with non-dopaminergic neurons in the same cultures. If this explanation is correct, then
our findings suggest that dopaminergic neurons may have lower capacity for protein degrada-
tion than other neuron types, resulting in accumulation of DD-Akt(E40K) even when TMP is
not present. There is much evidence that neurodegeneration in PD is associated with inade-
quate degradation and consequent accumulation of misfolded and aggregated proteins [55,
56], and there are reports of selectively compromised protein degradation by dopaminergic
neurons in this disorder [57, 58]. Our findings raise the possibility that dopaminergic neurons
are less efficient than several other neuron types in protein clearance. If so, this in turn suggests
a potential reason for the selective susceptibility of dopaminergic neurons in PD.
Our data indicate that cellular context plays an important role in determining the basal and
induced levels of DD-Akt(E40K). Although dopaminergic neurons may not provide the opti-
mal cellular environment for DD-Akt(E40K) induction, our findings show relatively low basal
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expression and robust induction in several other cell types. In 293 cells, induction of DD-Akt
(E40K) was correlated with enhanced phosphorylation of FoxO4 and in PC12 cells correlated
with promotion of survival in multiple models. Thus, in appropriate cell types, DD-Akt(E40K)
may be a useful tool to interrogate the molecular, physiologic and pathologic effects of elevat-
ing Akt levels and activity in a tunable, reversible and selective manner. Induction of DD-Akt
(E40K) in the striatum additionally supports the idea of using such a reagent in vivo and poten-
tially, for therapeutic purposes. For instance, there is evidence linking defective Akt signaling
with insulin resistance [59]. In the nervous system, Akt dysfunction has been associated with a
variety of mood disorders [12, 15, 16] and Akt over-expression with promotion of CNS axon
regeneration and neuron survival after injury [60]. Given the pathophysiological consequences
of dysregulated Akt activity in the CNS, DD-Akt(E40K) (and related constructs) may represent
an approach to enhance Akt function in disorders associated with diminished Akt expression
and/or activity.
Supporting information
S1 Fig. Comparison of loading controls for transduction experiments. Upper image shows
western blot of EGFP (GFP) and ERK loading controls for an experiment in which replicate
cultures of PC12 cells were infected with lentivirus expressing either DD-Akt(E40K) or DD2-
Akt(E40K) as indicated, and treated for 24 hr with or without TMP (10 μM) or 2xTMP
(20 μM) and then lysed. The infection efficiencies were 78.3% and 75.6%, respectively as deter-
mined by immunofluorescence imaging for EGFP. Blots were probed for ERK and EGFP
(GFP) proteins and relative intensities of the indicated bands were determined as described in
Materials and Methods. Relative intensities are given in Arbitrary Units (A.U.) for each indi-
vidual replicate for both GFP and ERK1 as well as the ratios thereof. Mean values for each
transfection condition (DD-Akt or DD2-Akt) are given in italics ± S.E.M. and indicate consis-
tency of transfection from replicate to replicate and of the GFP/ERK1 ratio.
(TIF)
S2 Fig. Uncropped blots with molecular weight markers for Fig 1E (panels A-C) and 4A
(panels D,E). Blot for total Akt is more highly exposed than in Fig 1 to show background. In
each panel 6 irrelevant lanes to the right are not included.
(TIF)
S3 Fig. E40K mutation does not affect DD-mediated destabilization of DD-Akts. HEK293
cells were transfected with DD constructs with WT Akt or Akt(E40K). Cells were treated with
10 μM TMP for 24 hr and then lysed for western blotting. Protein expression levels were quan-
tified and normalized to ERK1 as a loading control. Fold induction was calculated as a ratio of
protein levels with TMP treatment divided by Akt(WT) protein levels without TMP treatment.
Graph shows means with SEM. N = 3 replicate samples per condition. p< 0.0001; n.s. vs.
DD-Akt(WT)–TMP unless otherwise indicated, 2-way ANOVA with multiple comparisons.
(TIF)
S4 Fig. Adding a second DD domain does not change inducibility or basal activity.
HEK293 cells were transfected with constructs to overexpress single DD domain Akt(E40K) or
double DD domain Akt(E40K) with varying linker combinations. Cells were treated with
10 μM TMP for 24 hr and then lysed for western blotting. Protein expression levels were quan-
tified and normalized to ERK1 as a loading control. Fold induction was calculated as a ratio of
protein levels with TMP treatment divided by protein levels without TMP treatment. Graph
shows means with SEM. N = 2 independent experiments with 2–3 replicates per condition per
experiment. p< 0.05 vs. DD-Akt(E40K), n.s. determined through 2-way ANOVA with
Conditionally-inducible Akt
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